Ventyx Biosciences Reports Positive Phase 2 Data for Oral NLRP3 Inhibitor VTX3232 in Obesity and Cardiovascular Risk
Ventyx Biosciences Inc. (NASDAQ:VTYX) is one of the best NASDAQ stocks under $5 to buy now.
Ventyx Biosciences Inc. (VTYX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.31 | 130,000 | $300,573.00 | 130,000 | 2024-12-23 | Filing | |
| $2.01 | 261,752 | $524,943.64 | 2,175,028 | 2024-11-25 | Filing | |
| $1.83 | 238,248 | $434,945.55 | 1,913,276 | 2024-11-22 | Filing | |
| $16.00 | 625,000 | $10,000,000.00 | 1,410,303 | 2021-10-25 | Filing | |
| $16.00 | 312,500 | $5,000,000.00 | 3,997,269 | 2021-10-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.07 | 1,887 | $2,019.09 | 467,226 | 2025-04-02 | Filing | |
| $2.36 | 21,119 | $49,840.84 | 464,582 | 2024-12-27 | Filing | |
| $2.26 | 13,161 | $29,682.00 | 485,701 | 2024-12-19 | Filing | |
| $5.40 | 1,651 | $8,921.34 | 284,999 | 2024-04-02 | Filing | |
| $5.40 | 1,651 | $8,921.01 | 264,998 | 2024-04-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 142,193 | $442,220 | 0.01% | |
| 2. | 47,295 | $147,087 | 0% | |
| 3. | 1,712 | $5,325 | 0% | |
| 4. | 870 | $2,706 | 0% | |
| 5. | 830 | $2,581 | 0% |
News See All
11 Best NASDAQ Stocks Under $5 to Buy Now
On October 9, Scott Ladner, Chief Investment Officer at Horizon Investments, appeared on CNBC to suggest that AI remains the key market driver along with tech.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen and welcome to the Ventyx Biosciences First Quarter 2024 Earnings Conference Call.
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.
25 Biggest Stocks with Negative Beta
Stock markets were in see-saw mode before the Fed’s September decision on rate hikes.
Long-Term Returns of Dan Loeb's 5 Activist Targets
The investment came amid Loeb’s confidence about SentinelOne, Inc. (NYSE:S)’s growth potential and ability to disrupt the cyber security industry.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Second Quarter 2023 Earnings Conference Call.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences First Quarter 2023 Earnings Conference Call.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Fourth Quarter and Full Year 2022 Earnings Conference Call.
10 Best-Performing Non-Energy Stocks of 2022
On Friday, September 16, Wall Street concluded another one of its abysmal weeks in months, as investors reacted to a weak earnings indication from FedEx regarding the global economy.
Hedge Fund Resource Center Billionaire Hedge Funds
